In 2024, David A. Ricks earned $7.75M in total compensation at Eli Lilly, including $1.69M salary and $5.71M bonus. Most recently acquired 55,132 shares in Feb 2025. Currently holds stock worth $526.39M. Has donated $167.84M in stock to charitable causes. 8+ years at the helm of Eli Lilly.
Compensation History
Annual executive compensation data for David A. Ricks, including salary, bonuses, and stock awards.
Year
2024
Total Compensation
$7.75M
Salary
$1.69M
Bonus
$5.71M
Other
$351.69K
Salary
$1.69MBoard Justification
Our compensation programs are designed to align executive pay with shareholder interests and link pay to performance through a blend of short- and long-term performance measures.
Bonus
$5.71MBoard Justification
The Committee updated the Bonus Plan for 2024, which now equally weights product revenue, EPS, and pipeline progress. The revenue metric focuses on new products, and the pipeline metric enhances visibility on deliverables by therapeutic area. Goals and weightings are set annually based on the operating plan and pipeline objectives
Other Compensation
$351.69KBoard Justification
Includes 401(k) and Nonqualified Savings Plan company matching contributions of $101,423, costs related to security services of $73,630, costs related to ancillary non-business travel or events associated with attendance at the Paris events of $35,374, tax reimbursements for imputed income related to this trip of $27,099, and aggregate incremental cost for his personal use of the corporate aircraft of $114,159.
Restricted Stock
Board Justification
N/A
Performance Metrics
Adjusted non-GAAP EPS, Total Shareholder Return, Revenue
David A. Ricks
CEO of Eli Lilly
Education
Bachelor's degree from Purdue University
Sector of Economy
Healthcare
Born
May 4, 1967 - 58 years ago
CEO of Eli Lilly for
8 years 11 months (Jan 2017 - Present)
Previous Experience
President of Lilly Bio-Medicines
Other Eli Lilly CEOs
Holdings
Track David A. Ricks's stock holdings and portfolio value over time.
Total Stock Sold
$1.33M
$1.33M
19,735 LLY shares
What if they kept their stock?
If David A. Ricks didn't sell their stock, today they would have:
Extra LLY19,735 shares worth $20.02M.
This is 1,404.97% and $18.69M more than what they got when they sold the stock.
Charitable Transactions
165,441 shares
LLY
Recent Charitable Transactions
13,727 shares
LLY
Aug 20, 2024
Charity
956 shares
LLY
Feb 8, 2024
Charity
15,000 shares
LLY
Nov 14, 2023
Charity
9,550 shares
LLY
Aug 9, 2023
Charity
4,200 shares
LLY
Feb 10, 2023
Charity
32,467 shares
LLY
Dec 31, 2022
Charity
Insider Trading
David A. Ricks's recent stock transactions, purchases, and sales filed with the SEC.
$47.90M
LLY at $868.88/share
Feb 10, 2025
Received
13,727 shares
LLY
Aug 20, 2024
Charity
$28.30M
LLY at $737.26/share
Feb 12, 2024
Received
956 shares
LLY
Feb 8, 2024
Charity
15,000 shares
LLY
Nov 14, 2023
Charity
9,550 shares
LLY
Aug 9, 2023
Charity
$19.40M
LLY at $345.12/share
Feb 10, 2023
Received
4,200 shares
LLY
Feb 10, 2023
Charity
$336.67K
ADBE at $280.56/share
Sep 27, 2022
Purchase
32,467 shares
LLY
Dec 31, 2022
Charity
Rivals
Compare David A. Ricks with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M
Robert A. Bradway
CEO of Amgen
2024 Compensation
Stock
$0.00
Salary
$1.87M
Bonus
$0.00
Other
$714.33K
Total Holdings
$269.12M